Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Study to Assess the Safety of REMdesivir-HU as Eligible Novel therapY for Moderate and Severe Covid-19 Patients

NCT04610541 is registered in ClinicalTrials.gov with University of Pecs as lead sponsor.

NCT NCT04610541
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04610541 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Study to Assess the Safety of REMdesivir-HU as Eligible Novel therapY for Moderate and Severe Covid-19 Patients
Lead sponsor
University of Pecs
Phase
Phase 3
Overall status
Unknown status
Start date
October 12, 2020
Completion date
November 30, 2021
Enrollment
2,000 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2 infection